RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 232 participants.
Also called NCT05134012
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 232 participants
- Sponsor
- MedTrace Pharma A/S
- Registry
-
NCT05134012
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Denmark, Germany, Netherlands, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT05134012. Allocation not applicable; no masking; primary purpose diagnostic. Start 2022-05-08 (actual); primary completion 2026-10-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
- Lead sponsor
- MedTrace Pharma A/S
Record details
- Record id
cardio:ct-nct05134012- Content hash
d2f06649c38000b7ae87700a0422ff7964c84138684f62d40e5ab38c7fb1f6dd